Cargando…
Management of hepatitis B virus reactivation due to treatment of COVID-19
The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B v...
Autores principales: | Yip, Terry Cheuk-Fung, Gill, Madeleine, Wong, Grace Lai-Hung, Liu, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889512/ https://www.ncbi.nlm.nih.gov/pubmed/35235148 http://dx.doi.org/10.1007/s12072-022-10306-x |
Ejemplares similares
-
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
por: Liang, Lilian Yan, et al.
Publicado: (2023) -
Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020) -
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2021) -
Alanine Aminotransferase Level: The Road to Normal in 2021
por: Yip, Terry Cheuk‐Fung, et al.
Publicado: (2021) -
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)